DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer

Biomolecules

Denis Velic⁴  Anthony M. Couturier⁴  Maria Tedim Ferreira³  Amélie Rodrigue⁴  Guy G. Poirier³  Fabrice Fleury¹  Jean-Yves Masson⁴  Wolf-Dietrich Heyer²  Thomas Helleday² 

[1] DNA repair regulation team, UFIP, CNRS UMR 6286, Université de Nantes, 2 rue de la Houssinière, Nantes 44322, France; E-Mail:Genome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Axis, 9 McMahon, Québec City, QC G1R-2J6, Canada;;Department of Molecular Biology, Medical Biochemistry and Pathology, Centre de Recherche sur le Cancer, Laval University, Québec City, QC G1V-0A6, Canada; E-Mails:;Genome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Axis, 9 McMahon, Québec City, QC G1R-2J6, Canada; E-Mails:

关键词: DNA repair;    inhibitors;    ATM;    ATR;    CHK1;    CHK2;    MRE11;    RAD51;    PARP;   

DOI  :  10.3390/biom5043204

来源: mdpi

【 摘 要 】

For decades, radiotherapy and chemotherapy were the two only approaches exploiting DNA repair processes to fight against cancer. Nowadays, cancer therapeutics can be a major challenge when it comes to seeking personalized targeted medicine that is both effective and selective to the malignancy. Over the last decade, the discovery of new targeted therapies against DNA damage signalling and repair has offered the possibility of therapeutic improvements in oncology. In this review, we summarize the current knowledge of DNA damage signalling and repair inhibitors, their molecular and cellular effects, and future therapeutic use.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.